

Cultivating Compassion



DURDANS
HOSPITAL

FINANCIAL STATEMENTS
CEYLON HOSPITALS PLC

FOR THE 2ND QUARTER ENDED 30TH SEPTEMBER 2024

Consolidated Statement of Profit or Loss and Other Comprehensive Income

	Group		Company		Group		Company	
	03 Months Ended 30/09/2024 Unaudited Rs. '000	03 Months Ended 30/09/2023 Unaudited Rs. '000	03 Months Ended 30/09/2024 Unaudited Rs. '000	03 Months Ended 30/09/2023 Unaudited Rs. '000	06 Months Ended 30/09/2024 Unaudited Rs. '000	06 Months Ended 30/09/2023 Unaudited Rs. '000	06 Months Ended 30/09/2024 Unaudited Rs. '000	06 Months Ended 30/09/2023 Unaudited Rs. '000
Revenue	2,469,067	2,260,579	1,441,481	1,357,818	4,705,687	4,460,974	2,782,006	2,583,647
Cost of Sales	(1,031,517)	(1,055,865)	(603,310)	(644,307)	(1,990,513)	(2,059,432)	(1,184,614)	(1,210,512)
Gross Profit	1,437,550	1,204,714	838,171	713,511	2,715,174	2,401,542	1,597,392	1,373,135
Other Operating Income	1,705	85,250	17,725	18,362	44,153	116,857	34,279	31,435
Administrative Expenses	(921,761)	(819,185)	(574,010)	(503,746)	(1,808,777)	(1,619,657)	(1,141,550)	(1,010,529)
Other Operating Expenses	(339,965)	(310,220)	(180,474)	(144,840)	(638,544)	(615,322)	(342,392)	(300,571)
Results from Operating Activities	177,529	160,559	101,411	83,287	312,006	283,420	147,729	93,470
Finance Cost	(63,324)	(43,353)	(72,269)	(35,506)	(144,773)	(87,529)	(161,650)	(70,516)
Finance Income	8,570	30,619	622	3,266	37,540	69,620	145,466	169,557
Profit before Taxation	122,775	147,825	29,765	51,047	204,774	265,511	131,545	192,511
Taxation	(39,355)	(48,222)	(27,856)	(13,000)	(98,650)	(133,247)	(32,276)	(41,758)
Net Profit after Taxation	83,420	99,603	1,909	38,047	106,124	132,264	99,269	150,753
Other Comprehensive Income								
Items will not be reclassified to profit or loss								
Net Change in Fair Value on Equity								
Investments at FVTOCI	(6,613)	3,988	(266)	(266)	(4,162)	2,250	687	(2,021)
Other Comprehensive Income for the period	(6,613)	3,988	(266)	(266)	(4,162)	2,250	687	(2,021)
quarter	76,807	103,591	1,642	37,781	101,962	134,514	99,956	148,732
Profit Attributable to:								
Equity Holders of the Parent	74,648	98,588	956	38,047	84,404	118,012	99,269	150,753
Non-Controlling Interest	8,772	1,015	-	-	21,719	14,252	-	-
	83,420	99,603	956	38,047	106,124	132,264	99,269	150,753
Total Comprehensive Income Attributable to:								
Equity Holders of the Parent	69,230	101,774	1,642	37,781	81,156	119,457	99,956	148,732
Non-Controlling Interest	7,577	1,817	-	-	20,806	15,057	-	-
	76,807	103,591	1,642	37,781	101,962	134,514	99,956	148,732
Earnings per Share - Basic	2.07	2.74	0.03	1.06	2.35	3.28	2.76	4.19

The above figures are provisional and subject to audit.

CEYLON HOSPITALS PLC

Financial Statements for the quarter ended 30th September 2024

Consolidated Statement of Financial Position


		GROUP		COMPANY	
		Unaudited	Unaudited	Unaudited	Unaudited
		As at	As at	As at	As at
		30/09/2024	30/09/2023	30/09/2024	30/09/2023
		Rs. '000	Rs. '000	Rs. '000	Rs. '000
ASSETS					
Non-Current Assets					
11,582,383	8,241,211	11,428,698	7,933,440	8,166,039	4,753,604
72,479	66,091	79,548	3,086,613	72,045	3,079,688
1,365	-	1,204	940	-	-
363,571	363,571	352,626	312,013	352,626	312,013
-	1,493,625	-	-	1,493,625	1,457,821
289,393	72,066	189,246	291,334	74,114	75,795
12,309,191	10,236,564	12,051,322	11,624,340	10,158,449	9,678,921
Current Assets					
814,311	642,259	818,303	868,595	602,614	663,367
312,866	199,904	351,450	356,766	219,154	201,778
291,390	164,155	311,605	544,022	171,686	269,933
5,385	66,372	7,068	4,894	104,011	281,990
899,205	45,529	1,007,272	782,001	195,988	44,625
44,254	37,260	38,816	13,400	34,845	13,400
366,451	212,125	212,302	314,142	87,159	205,949
2,733,862	1,367,604	2,746,817	2,883,820	1,415,457	1,681,042
15,043,053	11,604,168	14,798,139	14,508,160	11,573,906	11,359,963
Total Assets					
EQUITY AND LIABILITIES					
Equity Attributable to Equity holders of the parent					
1,142,798	1,142,798	1,692,704	1,142,798	1,692,704	1,142,798
2,290,344	1,742,664	2,290,344	2,290,344	1,742,664	1,742,664
74,340	(659)	71,092	78,289	28	4,291
4,595,643	2,963,955	4,605,015	4,297,027	2,988,191	2,880,209
8,103,125	5,848,758	8,659,154	7,808,458	6,423,587	5,769,962
733,044	-	724,561	710,755	-	-
8,836,169	5,848,758	9,383,715	8,519,213	6,423,587	5,769,962
Non-Current Liabilities					
1,989,051	1,872,910	1,232,074	2,038,608	1,113,661	1,875,432
279,087	279,087	257,098	257,122	257,098	257,122
-	28,580	-	-	27,635	29,525
227,265	203,793	244,261	209,969	221,845	187,080
1,389,826	1,063,004	1,427,630	1,297,938	1,092,860	995,120
-	467,500	-	-	446,250	467,500
3,885,229	3,914,874	3,161,063	3,803,637	3,159,349	3,811,779
Current Liabilities					
542,805	413,050	511,960	530,236	424,490	386,742
488,626	428,928	482,045	503,382	433,118	473,693
120,416	120,416	120,416	100,500	120,416	100,500
1,027,015	551,023	1,091,028	989,178	543,969	537,912
-	-	21,991	48,603	-	27,404
142,793	327,119	25,921	13,411	468,976	251,971
2,321,655	1,840,536	2,253,361	2,185,310	1,990,967	1,778,222
15,043,053	11,604,168	14,798,139	14,508,160	11,573,906	11,359,963
Total Equity and Liabilities					


The above figures are provisional and subject to audit.


 Thusitha Rubasinghe
 Chief Financial Officer

The Board of Directors is responsible for the preparation and presentation of these Financial Statements.

Signed for and on behalf of the Board by,


 A E Tudawe
 Chairman


 U D Tudawe
 Director

12th November 2024

CEYLON HOSPITALS PLC
Consolidated Statement of Changes in Equity

Group	Attributable to equity holders of the parent					Non-Controlling Interests Rs. '000	Total Equity Rs. '000
	Stated Capital Rs. '000	Revaluation Reserve Rs. '000	Fair Value Reserve Rs. '000	Revenue Reserves Rs. '000	Total Rs. '000		
Balance as at 31st March 2023 -Audited	1,142,798	2,290,344	76,843	4,261,864	7,771,850	729,501	8,501,350
Net Profit for the year ended 31 March 2024	-	-	-	417,194	417,194	36,618	453,812
Other Comprehensive Income							
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	(2,503)	-	(2,503)	1,037	(1,466)
Actuarial Gain on Gratuity Valuation	-	-	-	673	673	(265)	408
Deferred Tax effect on Gratuity Valuation	-	-	-	(755)	(755)	(45)	(800)
Total Comprehensive Income for the year ended 31 March 2024	-	-	(2,503)	417,112	414,609	37,345	451,954
Transactions with Owners in their capacity as Owners							
Rights Issue Expenses	-	-	-	(557)	(557)	-	(557)
Dividend Paid - Ordinary Shares	-	-	-	(82,776)	(82,776)	(33,802)	(116,578)
	-	-	-	(83,333)	(83,333)	(33,802)	(117,135)
Balance as at 31st March 2024 -Audited	1,142,798	2,290,344	74,340	4,595,643	8,103,125	733,044	8,836,169
Net Profit for the quarter ended 30 September 2024	-	-	-	84,404	84,404	21,719	106,124
Other Comprehensive Income							
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	(3,248)	-	(3,248)	(913.55)	(4,162)
Total Comprehensive Income for the quarter ended 30 September 2024	-	-	(3,248)	84,404	81,156	20,806	101,962
Transactions with Owners in their capacity as Owners							
Shares issued at Rights Issue	549,906	-	-	-	549,906	-	549,906
Rights Issue Expenses	-	-	-	(3,053)	(3,053)	-	(3,053)
Dividend Paid - Ordinary Shares	-	-	-	(71,980)	(71,980)	(29,289)	(101,269)
Balance as at 30th September 2024	1,692,704	2,290,344	71,092	4,605,015	8,659,155	724,561	9,383,716

Company

	Stated Capital Rs. '000	Revaluation Reserve Rs. '000	Fair Value Reserve Rs. '000	Revenue Reserves Rs. '000	Total Rs. '000
Balance as at 31st March 2023 - Audited	1,142,798	1,742,664	6,312	2,812,305	5,704,079
Net Profit for the year ended 31 March 2024	-	-	-	233,631	233,631
Other Comprehensive Income					
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	(6,971)	-	(6,971)
Actuarial Gain on Gratuity Valuation	-	-	-	1,931	1,931
Deferred Tax Effect on Gratuity Valuation	-	-	-	(579)	(579)
Total Comprehensive Income for the year ended 31 March 2024	-	-	(6,971)	234,983	228,012
Transactions with Owners in their capacity as Owners					
Rights Issue Expenses	-	-	-	(557)	(557)
Dividend Paid - Ordinary Shares	-	-	-	(82,776)	(82,776)
	-	-	-	(83,333)	(83,333)
Balance as at 31st March 2024 - Audited	1,142,798	1,742,664	(659)	2,963,955	5,848,758
Net Profit for the quarter ended 30 September 2024	-	-	-	99,269	99,269
Other Comprehensive Income					
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	687	-	687
Total Comprehensive Income for the quarter ended 30 September 2024	-	-	687	99,269	99,955
Transactions with Owners in their capacity as Owners					
Shares issued at Rights Issue	549,906	-	-	-	549,906
Rights Issue Expenses	-	-	-	(3,053)	(3,053)
Dividend Paid - Ordinary Shares	-	-	-	(71,980)	(71,980)
Balance as at 30th September 2024	1,692,704	1,742,664	28	2,988,192	6,423,587

Consolidated Statement of Cash Flows

Group Audited 12 Months Ended 31/03/2024 Rs '000	Company Audited 12 Months Ended 31/03/2024 Rs '000	Group		Company		
		Unaudited 06 Months Ended 30/09/2024 Rs '000	Unaudited 06 Months Ended 30/09/2023 Rs '000	Unaudited 06 Months Ended 30/09/2024 Rs '000	Unaudited 06 Months Ended 30/09/2023 Rs '000	
		Cash Flows from/ (Used in) Operating Activities				
658,886	293,937	Net Profit Before Income Tax Expenses	204,774	265,511	131,545	192,511
		Adjustments for :				
26,519	18,537	Inventory Write-off/(Write in)	15,609	34,477	14,424	27,767
49,230	39,240	Bad Debts Write-off	4,563	4,723	4,563	4,723
442,576	230,162	Depreciation Charge	284,500	215,338	167,554	109,966
124,577	124,577	Amortisation of Right of use assets	69,036	60,055	69,036	60,055
(99,656)	(171,816)	Finance Income	(37,540)	(69,620)	(145,466)	(169,557)
144,669	147,984	Finance Cost	144,773	87,529	161,650	70,516
-	(1,890)	Amortisation of Deferred Rent Expenses/(Income)	-	-	(945)	(945)
(17,755)	(1,550)	(Profit)/ Loss on Disposal of Property, Plant and Equipment	(29,500)	(5,367)	-	-
-	-	(Profit)/ Loss on Disposal of Financial Instruments	(3,085)	(69,580)	(3,085)	(2,235)
(102,117)	(2,079)	Fair value (Gain)/Loss on Financial Instruments	14,160	(1,113)	(3,312)	(1,113)
(1,113)	(1,113)	Unclaimed Dividends	-	-	-	-
(160)	-	Creditors written back	-	-	-	-
19,814	-	Unclaimed VAT	-	-	-	-
57,627	50,804	Provision for Defined Benefit Plans	32,994	20,532	30,144	18,013
1,303,097	726,793	Operating Profit before Working Capital Changes	700,283	542,485	426,106	309,701
179,302	146,797	(Increase)/Decrease in Inventories	(19,601)	117,061	25,222	116,460
330,379	130,061	(Increase)/Decrease in Trade and Other Receivables	(63,363)	98,169	(30,886)	56,926
147,995	100,441	Increase/(Decrease) in Trade and Other Payables	64,013	109,998	(7,052)	100,104
142,738	252,236	(Increase)/Decrease Related Party Dues	(118,555)	13,846	81,288	(46,726)
2,103,511	1,356,328	Cash Generated from Operations	562,777	881,559	494,678	536,465
(144,669)	(120,885)	Finance Cost Paid	(144,773)	(75,467)	(161,650)	(56,038)
(35,369)	(27,807)	Defined Benefit Plan Costs Paid	(15,997)	(15,978)	(12,092)	(13,660)
(198,041)	(60,608)	Income Tax/WHT Paid	(38,749)	(166,400)	(8)	(58,656)
1,725,432	1,147,028	Net Cash from Operating Activities	363,258	623,714	320,929	408,111
		Cash Flows from/ (used in) Investing Activities				
(958,307)	(480,682)	Acquisition of Property, Plant and Equipment	(122,027)	(924,928)	(98,336)	(710,415)
(827,135)	(823,939)	Acquisition of Capital work in progress	-	-	-	-
(1,600)	-	Purchase of Intangible Assets	-	(940)	-	-
6,430	1,550	Proceeds from Sale of Property, Plant and Equipment	29,500	5,367	-	-
42,879	-	Proceeds on Sale of Shares/Units	-	-	-	-
(50,184)	(32,175)	(Acquisition)/ Disposal of other Investments	(23,729)	74,617	(153,768)	3,522
99,657	171,816	Income from Investments	37,540	69,620	151,863	169,557
(1,688,260)	(1,163,430)	Net Cash Flows from/ (used in) Investing Activities	(78,715)	(776,264)	(100,241)	(537,336)
		Cash Flows from/ (used in) Financing Activities				
375,000	360,000	Receipts from Interest Bearing Loans and Borrowings	-	300,000	-	300,000
(254,128)	(194,712)	Re-payments to Interest Bearing Loans and Borrowing	(776,523)	(114,816)	(755,059)	(87,426)
(154,378)	(154,379)	Lease Rent Payment	(76,907)	(69,193)	(76,907)	(69,193)
-	-	Proceeds on Shares issued at Rights Issue	549,906	-	549,906	-
(557)	(557)	Right Issue Expenses	(3,053)	(73)	(3,053)	(73)
(116,579)	(82,776)	Dividends Paid	(101,269)	(116,578)	(71,980)	(82,776)
(150,642)	(72,424)	Net Cash Flows from/ (used in) Financing Activities	(407,846)	(660)	(357,093)	60,532
(113,470)	(88,825)	Net Increase/ (Decrease) in Cash and Cash Equivalents	(123,303)	(153,210)	(136,405)	(68,693)
(62,884)	(112,100)	Cash and Cash Equivalents at the Beginning of the Year	(176,354)	(62,884)	(200,925)	(112,100)
(176,354)	(200,925)	Cash and Cash Equivalents at the End of the Period	(299,657)	(216,094)	(337,330)	(180,793)
		Analysis of Cash and Cash Equivalents				
(542,805)	(413,050)	Bank Overdraft	(511,960)	(530,236)	(424,490)	(386,742)
366,451	212,125	Cash in Hand and at Bank	212,302	314,142	87,159	205,949
(176,354)	(200,925)		(299,657)	(216,094)	(337,330)	(180,793)

Explanatory Notes

01. CORPORATE INFORMATION

Ceylon Hospitals PLC is a public limited company incorporated and domiciled in Sri Lanka and listed on the Colombo Stock Exchange. Ordinary shares of the company are listed on the Colombo Stock Exchange.

02. INTERIM CONDENSED FINANCIAL STATEMENTS

The financial statements for the quarter ended 30 September 2024, includes "the Company" referring to Ceylon Hospitals PLC, as the holding company and "the Group" referring to the companies whose accounts have been consolidated therein.

03. APPROVAL OF FINANCIAL STATEMENTS

The interim condensed financial statements of the Group and the Company for the quarter ended 30 September 2024 were authorised for issue by the Board of Directors on 12th November 2024.

04. BASIS OF PREPARATION AND CHANGES TO ACCOUNTING POLICIES

4.1 Basis of preparation

The interim financial statements for the quarter ended 30 September 2024 have been prepared in accordance with LKAS 34 Interim Financial Reporting.

The interim condensed financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 March 2024.

4.2 Fair value measurement and related fair value disclosures

The fair values of all the financial assets and financial liabilities recognised during the six months were not materially different from the transaction prices at the date of initial recognition. There were no transfers between Level 1 and Level 2 and no transfers into or out of Level 3 categories as per the fair value hierarchy, during the quarter. The fair value changes on financial instruments in Level 3 category was properly recorded in the statement of other comprehensive income and there were no purchases and/or disposals during the period.

Investments in quoted shares, Investments in Debentures and Refundable deposits are classified under non current financials assets while Investments in Unit Trusts, Investment in quoted shares (Trading) and Investments in Fixed Deposits are classified under current financial assets.

Recurring Fair Value Measurement As at 30th September 2024	Group				Company			
	Level 01 Rs.	Level 02 Rs.	Level 03 Rs.	Total Rs.	Level 01 Rs.	Level 02 Rs.	Level 03 Rs.	Total Rs.
<u>Fair Value through Other Comprehensive Income</u>								
Equity Shares in Listed Companies	19,925,347	-	-	19,925,347	1,484,457	-	-	1,484,457
	19,925,347	-	-	19,925,347	1,484,457	-	-	1,484,457

Recurring Fair Value Measurement As at 30th September 2024	Group				Company			
	Level 01 Rs.	Level 02 Rs.	Level 03 Rs.	Total Rs.	Level 01 Rs.	Level 02 Rs.	Level 03 Rs.	Total Rs.
<u>Fair Value through Profit or Loss</u>								
Equity Shares in Listed Companies	273,924,493	-	-	273,924,493	-	-	-	-
Investments in Unit Trusts	564,455,563	-	-	564,455,563	119,078,229	-	-	119,078,229
	838,380,056	-	-	838,380,056	119,078,229	-	-	119,078,229

05. There were no contingent liabilities as at the Balance Sheet date which would require adjustment or disclosure in the Financial Statements other than what is disclosed in the Annual Report 2023/2024.

06. Events occurring after the Balance Sheet date

The Board of Directors of CHPLC have approved the amalgamation of CHPLC and DHC on its meeting held on 27th September 2024 and the said amalgamation is expected to be effective from 1st January 2025 or such other date as may be determined by the Registrar General of Companies. The Company has already received the approval for amalgamation from Colombo Stock Exchange on 12th November 2024.

07. Related party transactions for the quarter ended 30 September 2024 were reviewed by the Related Party Transactions Review Committee and it was decided there were no transactions requiring Board Approval, immediate CSE disclosure or Shareholder approval.

Related Party Transactions
For the quarter ended 30 September 2024

Name of the Related Party	Relationship	Transactions	Nature	Aggregate Value of Related Party Transactions Rs'000
Durdans Management Services Ltd	Ultimate Parent	Management fee Paid Debenture Interest Received	Recurrent Recurrent	27,820 2,293
Durdans Medical and Surgical Hospital (Pvt) Ltd	Subsidiary	Sales of Drugs and consumables Rendering of medical services Sharing of utilities and other cost Dividend received Purchases of Drugs and consumables Receiving of medical services Receiving of utilities and other cost	Recurrent Recurrent Recurrent Recurrent Recurrent Recurrent	18,340 58,313 299,314 134,043 73,137 30,391 73,137
Durdans Heart Centre (Pvt) Ltd	Subsidiary	Sales of Drugs and consumables Rendering of medical services Sharing of utilities and other cost Dividend received Purchases of Drugs and consumables Receiving of medical services Receiving of utilities and other cost	Recurrent Recurrent Recurrent Recurrent Recurrent Recurrent	3,077 8,691 64,997 10,323 2,281 592 2,406
Amrak Institute of Medical Sciences (Pvt) Ltd	Subsidiary	Rent Received Providing utilities and other cost	Recurrent Recurrent	11,682 3,708
Ceygen Biotech (Pvt) Ltd	Subsidiary	Providing utilities and other cost Rent Received	Recurrent Recurrent	215 770
Commercial Marketing Distributors (Pvt) Ltd	Affiliate	Sale of Drugs and consumables Purchases of Drugs and consumables	Recurrent Recurrent	332 105,936
Tudawe Brothers (Pvt) Ltd	Affiliate	Vision 2022 Construction Cost	Non Recurrent	-
Tudawe Engineering Services (Pvt) Ltd	Affiliate	Vision 2022 Construction Cost	Non Recurrent	2,680

Share Information
Number of Shares Represented in Stated Capital

Voting Shares	30,997,401
Non-Voting Shares	10,133,765
Total	41,131,166

The voting shares of 3,874,675 and the non voting shares of 1,266,721 issued through Rights issue in June 2024 that was listed on Colombo Stock Exchange on 03rd July 2024 has been included in the share information above.

Public Shareholding as at 30th September 2024

	Voting	Non-Voting
Number of shareholders	2,389	1,330
Number of shares	6,544,140	5,095,055
Holding Percentage	21.11%	50.28%
Float Adjusted Market Capitalisation (Rs Mn)	759	
Float Adjusted Market Capitalisation Option	Less than 2.5 Bn (Option 5)	

Directors' and Chief Executive Officer's Shareholding as at 30th September 2024

	Number of Shares	
	Voting	Non-Voting
Mr. A. E. Tudawe	397,830	-
Mr. A. E. Tudawe (Joint Account)	125,240	-
Mr. U. D. Tudawe	335,014	-
Dr A. D. P. A. Wijegoonewardene	268,743	-
Mr. Y. N. R. Piyasena	597,824	-
Mr. A. D. B. Talwatte	1,213	-
Mr. A.V.R. De Silva Jayatilleke	121	-
Mr. A.S. Tudawe	51	1,062
Mr. S. Renganathan	-	-
Mr. H.M.A. Jayasinghe	-	-

Market Prices recorded during the Quarter

	Highest Traded Price		Lowest Traded Price		Last Traded Price	
	2024/25 Rs.	2023/24 Rs.	2024/25 Rs.	2023/24 Rs.	2024/25 Rs.	2023/24 Rs.
Voting	129.25 30/07/2024	135.00 15/09/2023	110.00 05/08/2024	115.00 45,111.00	116.00 30/09/2024	126.00 27/09/2023
Non - Voting	98.70 18/07/2024	121.00 02/08/2023	87.00 13/09/2024	101.25 06/07/2023	90.00 25/09/2024	110.00 19/09/2023

Per Share Ratios

	Group		Company	
	As at 30/09/2024 Rs.	As at 30/09/2023 Rs.	As at 30/09/2024 Rs.	As at 30/09/2023 Rs.
Earnings Per Share	2.35	3.28	2.76	4.19
Net Asset Per Share	210.53	216.96	156.17	160.32

Top 20 Shareholders Listed as at 30th September 2024

Voting Shareholders

Name of the Shareholder	Country of Residence	Number of Shares	Holding %
Durdans Management Services Ltd	Sri Lanka	21,574,963	69.60
Mr. D.G. Wijemanna	do	730,597	2.36
Mr. R.P. Weerasooriya	do	701,457	2.26
Mr. Y. N. R. Piyasena	do	597,824	1.93
Mr. Deen Mohamed Fazal Aslam	do	555,500	1.79
Galle Face Capital Partners PLC	do	518,791	1.67
Mr. A. E. Tudawe	do	397,830	1.28
Mr. Merrill J. Fernando (Deceased)	do	390,500	1.26
Cargo Boat Development Company PLC	do	370,945	1.20
Mr. U. D. Tudawe	do	335,014	1.08
MJF Holdings (Pvt) Ltd	do	287,917	0.93
Dr. A. D. P. A. Wijegoonewardene	do	268,743	0.87
Mr. H. L. Tudawe	do	253,626	0.82
Mr. A. D. Tudawe	do	246,682	0.80
Mr. P.V. Tudawe	do	219,920	0.71
Mr. A. D. Tudawe (Joint Account)	do	196,694	0.63
Mr. A. E. Tudawe (Joint Account)	do	125,240	0.40
Commercial Bank of Ceylon PLC A/C Nc	do	88,187	0.28
E.W. Balasuriya & Co. (Pvt) Ltd	do	86,006	0.28
Merrill J Fernando & Sons (Pvt) Ltd	do	80,914	0.26
		28,027,350	90.43

Non-Voting Shareholders

Name of the Shareholder	Country of Residence	Number of Shares	Holding %
Durdans Management Services Ltd	Sri Lanka	3,588,133	35.41
Employees' Provident Fund	do	1,154,371	11.39
MJF Holdings (Pvt) Ltd	do	636,061	6.28
E. W. Balasuriya & Co. (Pvt) Ltd	do	401,465	3.96
Mr. D. Ratnayake	do	156,045	1.54
Mr. L.J.M.A. Jayasundara	do	150,500	1.49
Tudawe Engineering Services (Pvt) Ltd	do	111,697	1.10
Mr. D. A. Cabraal	do	100,178	0.99
Mr. A. H. Munasinghe	do	98,141	0.97
Mr. S. S. Sithambaranathan	do	94,357	0.93
Mr. A. D. Tudawe	do	86,396	0.85
Ms. T. T. Weerasinghe	do	80,554	0.79
Mr. D. G. Wijemanna	do	77,728	0.77
Mr. P. S. De Mel	do	75,248	0.74
Peoples Leasing & Finance PLC /Mr. P. A	do	72,857	0.72
Saman Villas Limited	do	70,988	0.70
Commercial Bank of Ceylon PLC A/C Nc	do	64,918	0.64
Mr. G. D. M. Ranasinghe	do	62,857	0.62
Mr. D.P. L. De Mel	do	62,589	0.62
Mr. A. H. Munasinghe	do	61,269	0.60
		7,206,352	71.11

CEYLON HOSPITALS PLC

CORPORATE INFORMATION

Name of Company

Ceylon Hospitals PLC

Brand Name

DURDANS

Legal Form

A quoted public company with limited liability incorporated in Sri Lanka under the Companies Ordinance No.51 of 1938 and registered under the Companies Act No.07 of 2007.

Company Registration Number

PQ 113

Stocks Exchange Listing

The Ordinary Shares of the Company are listed on the Colombo Stock Exchange of Sri Lanka.

Registered Office

No.03, Alfred Place, Colombo 03.

Bankers

Bank of Ceylon
Commercial Bank of Ceylon PLC
DFCC Bank PLC
Hatton National Bank PLC
National Development Bank PLC
Nations Trust Bank PLC
Sampath Bank PLC
Seylan Bank PLC
Union Bank of Colombo PLC
People's Bank

Auditors

Messers.B.R.De.Silva & Co.
Chartered Accountants
No. 22/4, Vijaya Kumaratunga Mawatha
Colombo 05.

Lawyers

Mr. D.F.R. Jayamaha
Hector Jayamaha Law Office,
No.228,Thimbirigasyaya Road,
Colombo 05.

Secretaries

Nexia Corporate Consultants (Pvt) Ltd
No. 130, Level 02, Nawala Road,
Narahrenpita. Colombo 05.

Registrars

S S P Corporate Services (Pvt) Ltd
546, Galle Road,
Colombo 03.